Vivoryon Therapeutics AG (GB:0R3M) has released an update.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Vivoryon Therapeutics reports promising Phase 2 results from its VIVA-MIND study, highlighting varoglutamstat’s significant improvement in kidney function, despite the study’s discontinuation due to unmet endpoints in Alzheimer’s disease. This supports the potential advancement of varoglutamstat in treating diabetic kidney disease, reinforcing previous findings from the VIVIAD study. The drug continues to show a favorable safety profile, bolstering its prospects in clinical development.
For further insights into GB:0R3M stock, check out TipRanks’ Stock Analysis page.